ERBB2 and neoplasm: In addition, a new study revealed that the expression level of ADAMTS18 in HER2-positive breast tumor samples at the initial stage of post trastuzumab treatment is higher than that in recurrent HER2-positive tumor samples after post trastuzumab treatment, suggesting that ADAMTS18 can be responsible for a reference factor for drug resistance therapy (57).